Regeneron Reports the US FDA's Acceptance of Priority Review for REGEN-COV for the Treatment and Prophylaxis of COVID-19
Shots:
- The US FDA has accepted for priority review a BLA for REGEN-COV (casirivimab and imdevimab) to treat COVID-19 in non-hospitalized patients and as prophylaxis in certain individuals
- The BLA is based on P-III study assessing efficacy & safety of REGEN-COV to treat non-hospitalized patients already infected with SARS-CoV-2- and to prevent symptomatic infection in asymptomatic household contacts of SARS-CoV-2 infected individuals
- The second BLA submission focused on the treatment of patients hospitalized due to COVID-19 and is expected to be submitted later this year. The FDA has assigned a PDUFA date of Apr 13- 2022 and is currently planning to hold an advisory committee meeting to discuss this application in advance of that date
| Ref: Regeneron | Image: WRGB
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com